Quince Therapeutics, Inc.
quincetx.com
As featured in
Claim pageClaim
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
News
Quince Therapeutics Renames as IRulya Therapeutics, Advances Pulmonary Drug Development
Quince Therapeutics (NASDAQ:QNCX) has changed its name to IRulya Therapeutics Inc. , effective October 9, 2026, as the biotechnology company shifts its focus towards developing an inhaled treatment for several serious lung diseases.
Read more
Report
Quince Therapeutics Relaunches as IRulya Therapeutics with a Focus on the Clinical Development of LAM-001, Targeting a Key Pathway in Pulmonary Disease
Company common stock to trade on Nasdaq under the symbol
Read more
Report
Quince Therapeutics to Participate in September 2026 Investor Conferences QNCX Stock News
Quince Therapeutics announces participation in September investor conferences and ongoing clinical studies for LAM-001 therapy.Quiver AI SummaryQuince Therapeutics, Inc., a clinical stage biopharmaceutical company focused on developing innovative therapie
Read more
Report
Quince Therapeutics to Participate in September 2026 Investor Conferences
SOUTH SAN FRANCISCO, Calif., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Quince Therapeutics, Inc. (Nasdaq: QNCX), a clinical stage biopharmaceutical company...
Read more
Report
Quince Therapeutics Settles Approximately $16.4 Million of Debt
Quince Therapeutics, Inc. (Nasdaq: QNCX) today announced the successful settlement of the company's outstanding obligations under its loan from the European ...
Read more
Report
Quince Therapeutics Engages LifeSci Capital as its Exclusive Financial Advisor to Explore Strategic Alternatives
Read more
Report
Show more news